Antoine Monsel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11552006/publications.pdf

Version: 2024-02-01

29 papers	3,111 citations	430874 18 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	4031 citing authors

#	Article	IF	Citations
1	Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respiratory Medicine,the, 2022, 10, 180-190.	10.7	161
2	Comparison of 8 versus 15Âdays of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Medicine, 2022, 48, 841-849.	8.2	43
3	Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial. Journal of Clinical Medicine, 2022, 11, 2796.	2.4	8
4	One-year patient outcomes based on lung morphology in acute respiratory distress syndrome: secondary analysis of LIVE trial. Critical Care, 2022, 26, .	5.8	2
5	Occurrence of Candidemia in Patients with COVID-19 Admitted to Five ICUs in France. Journal of Fungi (Basel, Switzerland), 2022, 8, 678.	3.5	11
6	Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 307-317.	5.6	131
7	Role of miRâ€466 in mesenchymal stromal cell derived extracellular vesicles treating inoculation pneumonia caused by multidrugâ€resistant Pseudomonas aeruginosa. Clinical and Translational Medicine, 2021, 11, e287.	4.0	12
8	Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. Current Opinion in Infectious Diseases, 2021, 34, 156-168.	3.1	13
9	Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respiratory Medicine,the, 2021, 9, 851-862.	10.7	163
10	Preclinical efficacy and clinical safety of clinicalâ€grade nebulized allogenic adipose mesenchymal stromal cellsâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12134.	12.2	72
11	Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 1121-1131.	10.7	344
12	Intraoperative pulmonary hyperdistention estimated by transthoracic lung ultrasound: A pilot study. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 825-831.	1.4	5
13	The IASIS, INHALE and VAPORISE trials. Reasons for a triple failure: Study design, aminoglycosides dosing and technique of nebulisation. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 179-183.	1.4	11
14	Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 870-880.	10.7	202
15	Inoculation Pneumonia Caused by Coagulase Negative Staphylococcus. Frontiers in Microbiology, 2019, 10, 2198.	3.5	8
16	Mesenchymal Stem Cellâ€“Derived Extracellular Vesicles Decrease Lung Injury in Mice. Journal of Immunology, 2019, 203, 1961-1972.	0.8	81
17	A small step for sedation that may become a giant leap for critical care medicine. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 425-427.	1.4	5
18	Personalised mechanical ventilation in acute respiratory distress syndrome: the right idea with the wrong tools? â€“ Authors' reply. Lancet Respiratory Medicine,the, 2019, 7, e39.	10.7	3

#	Article	IF	Citations
19	Hospital-acquired pneumonia in ICU. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 83-98.	1.4	135
20	Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU. Annals of Intensive Care, 2018, 8, 104.	4.6	32
21	Mesenchymal Stem Cell Microvesicles Attenuate Acute Lung Injury in Mice Partly Mediated by Ang-1 mRNA. Stem Cells, 2017, 35, 1849-1859.	3.2	154
22	Modification of Tracheal Cuff Shape and Continuous Cuff Pressure Control to Prevent Microaspiration in an Ex Vivo Pig Tracheal Two-Lung Model. Critical Care Medicine, 2017, 45, e1262-e1269.	0.9	13
23	Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opinion on Biological Therapy, 2016, 16, 859-871.	3.1	156
24	Therapeutic Effects of Human Mesenchymal Stem Cellâ€“derived Microvesicles in Severe Pneumonia in Mice. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 324-336.	5.6	392
25	Study of Bone Marrow and Embryonic Stem Cell-Derived Human Mesenchymal Stem Cells for Treatment ofEscherichia coliEndotoxin-Induced Acute Lung Injury in Mice. Stem Cells Translational Medicine, 2015, 4, 832-840.	3.3	56
26	Human Mesenchymal Stem Cell Microvesicles for Treatment of Escherichia coli Endotoxin-Induced Acute Lung Injury in Mice. Stem Cells, 2014, 32, 116-125.	3.2	550
27	Cell-based Therapy for Acute Organ Injury. Anesthesiology, 2014, 121, 1099-1121.	2.5	127
28	Adult stem cells for acute lung injury: Remaining questions and concerns. Respirology, 2013, 18, 744-756.	2.3	38
29	Intermittent Subglottic Secretion Drainage and Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 910-917.	5.6	173